Dr Wilton David Mcrae, MD | |
1320 Highway 231 S, Suite 3, Troy, AL 36081-3000 | |
(334) 807-8448 | |
(334) 807-6099 |
Full Name | Dr Wilton David Mcrae |
---|---|
Gender | Male |
Speciality | |
Experience | Years |
Location | 1320 Highway 231 S, Troy, Alabama |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1093706905 | NPI | - | NPPES |
009962705 | Medicaid | AL | |
051512237 | Other | AL | BCBS/ENTERPRISE |
051552696 | Medicaid | AL | |
529402450 | Other | AL | MEDICAID BILLING GROUP # |
51523327 | Other | AL | BLUE CROSS BLUE SHIELD # |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Y00000X | Otolaryngology | 6245 (Alabama) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Wilton David Mcrae, MD 1330 Highway 231 S, Troy, AL 36081-3058 Ph: (334) 670-5474 | Dr Wilton David Mcrae, MD 1320 Highway 231 S, Suite 3, Troy, AL 36081-3000 Ph: (334) 807-8448 |
News Archive
Researchers have developed a spectroscopic microscope to enable optical measurements of molecular conformations and orientations in biological samples. The novel measurement technique allows researchers to image biological samples at the microscopic level more quickly and accurately.
Quick-Med Technologies, Inc., a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that it has signed a development agreement with Biosara Corporation, a medical device company targeting wound dressings for major medical and healthcare providers, along with the multi-billion dollar organized sports athlete markets.
Smokers who lie about their habit to their doctors could in future be caught out by a simple blood test.
Gilead Sciences, Inc. today announced the publication of data from DAR-311 (DORADO), a Phase III clinical trial evaluating the company's once-daily oral endothelin receptor antagonist (ERA) darusentan as an add-on treatment for resistant hypertension, defined as the failure to achieve blood pressure goal while adhering to full doses of an appropriate three (or more) drug antihypertensive regimen that includes a diuretic.
› Verified 1 days ago